Marker Therapeutics Announces First Patient Treated in Off-the-Shelf Program
Provided By GlobeNewswire
Last update: Oct 6, 2025
Marker Therapeutics initiated Phase 1 RAPID study to investigate Multi-Antigen Recognizing (MAR) T cells as an Off-the-Shelf (OTS) product to accelerate time to treatment
Read more at globenewswire.com
